Ari Mintz, DO
Interventional Cardiology · New York, NYNPI 1386907715
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Penumbra, Inc. accounts for 78.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $6,346 and has fallen 91.8% since, to $522 in 2025.
Across 64 payments — averaging $170.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$9K
- Boston Scientific$918
- Shockwave Medical, Inc$337
- Medtronic$217
- Abbott$214
- Boehringer Ingelheim$154
- plus $509 from 11 others
What the payments were for
- Speaking & faculty fees$6,00055%
- Travel & lodging$2,36022%
- Food & beverage$2,37422%
- Education$1581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 10 | $8,544 |
| Boston Scientific | 11 | $918 |
| Shockwave Medical, Inc | 4 | $337 |
| Medtronic | 2 | $217 |
| Abbott | 7 | $214 |
| Boehringer Ingelheim | 8 | $154 |
| Cagent Vascular Inc | 3 | $117 |
| Novartis | 5 | $99 |
| Johnson & Johnson | 4 | $75 |
| Pfizer | 2 | $53 |
| Alnylam Pharmaceuticals Inc. | 1 | $35 |
| Bayer | 1 | $27 |
| Amgen | 2 | $23 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Abiomed | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,892 in reported general payments places this provider in the 55th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $109,001 |
| XareltoRivaroxaban | 60 | $63,598 |
| EntrestoSacubitril/Valsartan | 12 | $11,401 |
| SantylCollagenase Clostridium Hist. | 11 | $3,112 |
| Clobetasol Propionate | 15 | $1,239 |
| Metoprolol Succinate | 72 | $1,169 |
| Atorvastatin Calcium | 103 | $1,105 |
| Ammonium Lactate | 42 | $845 |
| Rosuvastatin Calcium | 40 | $684 |
| Ezetimibe | 12 | $465 |
| Amlodipine Besylate | 39 | $274 |
| Chlorthalidone | 13 | $273 |
| Spironolactone | 15 | $205 |
| Nitroglycerin | 19 | $181 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $109,001109 claims |
| Johnson & JohnsonXarelto | $75 | $63,59860 claims |
| NovartisEntresto | $99 | $11,40112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- George DangasNew York$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.